Manioc : Portail | resultats 1 - 20 pour la recherche: Braun, Joséphine

Le pays de l'or : la Guyane française
Année de publication :

| Plus

Flora brasiliensis : enumeratio plantarum in Brasilia hactenus detectarum quas suis aliorumque botanicorum studiis descriptas et methodo naturali digestas partim icone illustratas. Volumen XIV, Pars II
Auteur(s) : Hooker, Joseph Dalton (1817-1911) Eichler, August Wilhelm (1837-1887) Engler, Adolf (1844-1930) Baker, John Gilbert (1834-1920) Rohrbach, Paul Schmidt, Johann Anton (1823-1905)
Auteurs secondaires : Martius, Karl Friedrich Philipp von (1794-1868)
Année de publication :

| Plus

Les colonies françaises : petite encyclopédie coloniale. Tome second, Congo, Madagascar et ses satellites, La Réunion, Côte des Somalis, Inde, Indo-Chine, Saint-Pierre et Miquelon, Antilles, Guyane, Nouvelle-Calédonie, Etablissement de l'Océanie, Appendices : 213 gravures, 25 cartes
Auteur(s) : Petit, Maxime (1858-1939)
Année de publication :

| Plus

Bulletin officiel de la Guyane française
Année de publication :

| Plus

Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Auteur(s) : Cotte, Laurent Braun, Joséphine Lascoux-Combe, Caroline Vincent, Corine Valantin, Marc-Antoine Sogni, Philippe Lacombe, Karine Neau, Didier
Auteurs secondaires : Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière] ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Pitié-Salpêtrière [APHP] Service des Maladies Infectieuses et Tropicales A [Bordeaux] ; CHU Bordeaux [Bordeaux] - Groupe hospitalier Pellegrin Service d'immunologie ; Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Européen Georges Pompidou [APHP] (HEGP) Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) CHU Pontchaillou [Rennes] Service de médecine interne et maladies infectieuses [Bordeaux] ; CHU Bordeaux [Bordeaux] - Groupe hospitalier Saint-André Service d'hépato-gastro-entérologie ; CHI Créteil Centre National de Référence Virus des hépatites B, C et Delta ; Institut National de la Transfusion Sanguine [Paris] (INTS) - Assistance publique - Hôpitaux de Paris (AP-HP)

Éditeur(s) : HAL CCSD Oxford University Press (OUP)
Résumé : International audience
Retreatment with pegylated interferon (peg-IFN) and ribavirin (RBV) results in poor sustained virological response (SVR) rates in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. There are limited data regarding the use of telaprevir plus peg-IFN/RBV in this population. HIV type 1-infected patients who previously failed ≥12 weeks of peg-IFN/RBV for HCV genotype 1 coinfection were enrolled in a single-arm, phase 2 trial. Patients with cirrhosis and previous null response were excluded. Authorized antiretrovirals were tenofovir, emtricitabine, efavirenz, atazanavir, and raltegravir. All patients received peg-IFN alfa-2a (180 µg/week) plus RBV (1000-1200 mg/day) for 4 weeks, followed by telaprevir (750 mg or 1125 mg every 8 hours with efavirenz) plus peg-IFN/RBV for 12 weeks and peg-IFN/RBV for 32-56 weeks according to virological response at week 8. The primary endpoint was the SVR rate at 24 weeks after the end of treatment (SVR24). Sixty-nine patients started treatment; SVR24 was achieved in 55 (80% [95% confidence interval, 68%-88%). SVR24 was not influenced by baseline fibrosis stage, IL28B genotype, antiretroviral regimen, HCV subtype, CD4 cell count, previous response to HCV treatment, HCV RNA level, or HCV RNA decline at week 4. HCV treatment was discontinued for adverse events (AEs) in 20% of patients, including cutaneous (4%), psychiatric (4%), hematological (6%), and other AEs (6%). Peg-IFN or RBV dose reduction was required in 23% and 43% of patients, respectively. Seventy percent of patients required erythropoietin, blood transfusions, or RBV dose reduction for anemia. Two patients died during the study. No HIV breakthrough was observed. Despite a high discontinuation rate related to toxicity, a substantial proportion of treatment-experienced HIV-coinfected patients achieved SVR24 with a telaprevir-based regimen. Clinical Trials Registration. NCT01332955.
ISSN: 1058-4838

hal-01118447
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01118447
PUBMED : 25139963
DOI : 10.1093/cid/ciu659

| Plus